Related Experiment Video

Updated: Feb 10, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.0K

MAGE-A antigens as targets for cancer immunotherapy

Erik Schooten1, Alessia Di Maggio2, Paul M P van Bergen En Henegouwen2

  • 1APO-T B.V., Kloosterstraat 9, 5349 AB Oss, The Netherlands.

Cancer Treatment Reviews
|May 16, 2018
PubMed

Insights

New cancer immunotherapies leverage MAGE antigens, which are intracellular proteins presented on cancer cell surfaces. This approach offers a promising avenue for developing targeted, patient-specific anti-cancer treatments with reduced side effects.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Targeted anti-cancer therapies seek to improve efficacy and reduce side effects.
  • Current immunotherapies face limitations due to a scarcity of cancer-specific targets.
  • Intracellular MAGE proteins, a class of Cancer Testis (CT) antigens, are expressed in various tumors and linked to pro-tumorigenic activities.

Purpose of the Study:

  • To review existing and ongoing clinical studies on MAGE antigens for targeted anti-cancer therapies.
  • To analyze the outcomes of these studies.
  • To discuss future directions and improvements for MAGE-directed immunotherapies.

Main Methods:

  • Review of preclinical and clinical studies focusing on MAGE antigens.
  • Analysis of study outcomes related to MAGE-targeted therapies.
  • Discussion of future research and therapeutic strategies.

Main Results:

  • MAGE proteins are processed and presented as peptides by MHC class I molecules on cancer cell surfaces.
  • Surface-expressed MAGE antigens serve as ideal targets for cancer-specific therapies.
  • Clinical studies are exploring the therapeutic potential of MAGE-directed immunotherapies.

Conclusions:

  • MAGE antigens represent a valuable target class for developing novel anti-cancer immunotherapies.
  • Targeting surface-expressed MAGE antigens offers potential for patient-tailored treatments.
  • Further research and optimization are needed to enhance the efficacy of MAGE-directed therapies.
Keywords:
Adoptive T cell therapyCancer immunotherapyCancer testis antigensMAGE

More Related Videos

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.7K
Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology08:27

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology

Published on: March 24, 2015

15.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Antigen Presenting Cells01:22

Antigen Presenting Cells

The immune system is a complex network of cells and molecules that protects the body from foreign invaders. T cells, a type of white blood cell, play a crucial role in this process. They recognize and attack foreign substances, such as pathogens, that enter the body.
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...
3.4K
Diversity of Antigen Receptors01:28

Diversity of Antigen Receptors

Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
1.7K
Antigen Processing Pathways01:31

Antigen Processing Pathways

MHC molecules are key players in the immune response, enabling T cells to recognize and respond to specific antigens. They are present on the surface of all nucleated cells in the body and are instrumental in presenting antigens to T cells and activating them. T cells recognize the MHC-antigen complex and initiate an immune response. MHC class I and MHC class II are two main types of MHC molecules, each associated with a distinct antigen processing pathway.
MHC Class I: Presenting Endogenous...
2.4K
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
1.6K